Table S3 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Autor: David J. Kwiatkowski, Gopa Iyer, Martin H. Voss, James J. Harding, Hebert A. Vargas, Geoffrey I. Shapiro, Anne Sisk, David M. Hyman, Junko Tsuji, Lynette M. Sholl, Katherine E. Kargus, Jennifer Hedglin, Matthew I. Milstein, Ketki Bhushan, Solida Pruitt-Thompson, Khanh T. Do, Krinio Giannikou, Katarzyna Klonowska, Elio Adib
Rok vydání: 2023
DOI: 10.1158/1078-0432.22480322
Popis: Table S3. Toxicities (any level) occurring in at least two patients, grouped by CTCAE v4.0 categories. For patients with more than one adverse event per category, only the highest-grade event was counted.
Databáze: OpenAIRE